Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | 8080799 | IM / LA |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | Y011819 | IM / LA |
INJECTION SITE PRURITUS; INJECTION SITE ERYTHEMA; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PRURITUS (INJECTION SITE PRURITUS) and VACCINATION SITE ERYTHEMA (INJECTION SITE ERYTHEMA) in a 73-year-old female patient who received mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (batch no. 8080799) for COVID-19 prophylaxis. Co-suspect product included non-company product Pneumococcal vaccine conj 21v (CRM197) (Capvaxive) for an unknown indication. Previously administered products included for Drug use for unknown indication: Codeine. Past adverse reactions to the above products included Drug allergy with Codeine. Concurrent medical conditions included Drug allergy (Codeine). On 15-Jan-2025, the patient received dose of mRNA-1273.712 (SPIKEVAX 2024-2025 PFS) (Intramuscular use) 1 dosage form and dose of Pneumococcal vaccine conj 21v (CRM197) (Capvaxive) (Intramuscular use) 1 dosage form. On 15-Jan-2025, the patient experienced VACCINATION SITE PRURITUS (INJECTION SITE PRURITUS) and VACCINATION SITE ERYTHEMA (INJECTION SITE ERYTHEMA). At the time of the report, VACCINATION SITE PRURITUS (INJECTION SITE PRURITUS) and VACCINATION SITE ERYTHEMA (INJECTION SITE ERYTHEMA) had not resolved. Concomitant medication was not reported. Patient had received 2 vaccines on 15-Jan-2025 (Spikevax and Capvaxive vaccines), and since then, patient had reported of redness and itching on the injection site. Patient called and reported that, the symptoms started on evening of 15-Jan-2025 and lasted until now. Hospitalization, emergency room or office visit was not required. Treatment medication was not reported.
Drug allergy (Codeine)